Skip to main content

Advertisement

SpringerLink
Log in

Levodopa-induced skin disorders in patients with Parkinson disease: a systematic literature review approach

  • Review article
  • Published:
Acta Neurologica Belgica Aims and scope Submit manuscript

Abstract

The use of levodopa for treatment of Parkinson’s disease is a well-established clinical practice. Data about the true incidence and severity of cutaneous complications associated with the use of levodopa are largely lacking. Aim of this review was to evaluate the quality of evidence referring to the skin disorders caused by levodopa treatment for Parkinson’s disease. Thirty of 1084 studies were included; 8 randomized controlled trials and 22 case reports in a total of 2749 patients. Malignant melanoma was the most frequent oral levodopa-related skin disorder followed by allergic cutaneous reactions, alopecia, vitiligo, skin hyperpigmentation, Laugier–Hunziker syndrome, Henoch–Schönlein syndrome, pseudobullous morphea and scleroderma-like illness. Naranjo scores ranged from 2 to 8. Regarding levodopa clinical trials, the most frequent skin complication was peripheral edema, followed by malignant melanoma. Although evidence is not robust, melanoma is the most frequent and possible fatal levodopa-associated skin disorder, while other skin allergic or immunological reactions are less common and reversible. Although levodopa treatment may induce melanogenesis and promote melanomagenesis, existing evidence does not support an association between levodopa therapy and induction or progression of malignant melanoma. The suggested association with melanoma may reflect the well-documented association of Parkinson’s disease with melanoma rather than the exposure to the drug. Nevertheless, until a solid conclusion can be drawn, the use of levodopa in the context of malignant melanoma should be considered with caution. Well-designed prospective studies are needed to determine the cause and effect relationship between levodopa and skin disorders.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Jankovic J (2017) Movement disorders in 2016: progress in Parkinson disease and other movement disorders. Nat Rev Neurol 13(2):76–78

    Article  PubMed  Google Scholar 

  2. Marras C, Chaudhuri KR (2016) Nonmotor features of Parkinson’s disease subtypes. Mov Disord 31:1095–1102

    Article  CAS  PubMed  Google Scholar 

  3. Tanner C, Albers K, Goldman S, Fross R, Leimpeter A, Klingman J et al (2012) Seborrheic dermatitis and risk of future Parkinson’s Disease. Neurology 78(1):2012

    Google Scholar 

  4. Egeberg A, Hansen PR, Gislason GH, Thyssen JP (2016) Exploring the association between rosacea and Parkinson disease: a Danish nationwide cohort study. JAMA Neurol 73(5):529–534

    Article  PubMed  Google Scholar 

  5. Ravn AH, Thyssen JP, Egeberg A (2017) Skin disorders in Parkinson’s disease: potential biomarkers and risk factors. Clin Cosmet Investig Dermatol 10:87–92

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Planken A, Kurvits L, Reimann E, Kadastik- Eerme L, Kingo K, Koks S et al (2017) Looking beyond the brain to improve the pathogenic understanding of Parkinson’s disease: implications of whole transcriptome profiling of Patients’ skin. BMC Neurol 17(1):6

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  7. Inzelberg R, Flash S, Friedman E, Azizi E (2016) Cutaneous malignant melanoma and Parkinson disease: common pathways? Ann Neurol 80(6):811–820

    Article  CAS  PubMed  Google Scholar 

  8. Disse M, Reich H, Lee PK, Schram SS (2016) A review of the association between Parkinson disease and malignant melanoma. Dermatol Surg 42(2):141–146

    Article  CAS  PubMed  Google Scholar 

  9. Liu R, Gao X, Lu Y, Chen H (2011) Meta-analysis of the relationship between Parkinson disease and melanoma. Neurology 76(23):2002–2009

    Article  PubMed  PubMed Central  Google Scholar 

  10. Goetz CG (2011) The history of Parkinson’s disease: early clinical descriptions and neurological therapies. Cold Spring Harb Perspect Med 1(1):a008862

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  11. Gregory R, Miller S (2015) Parkinson’s disease and the skin. Pract Neurol 15(4):246–249

    Article  PubMed  Google Scholar 

  12. Huang P, Yang XD, Chen SD, Xiao Q (2015) The association between Parkinson’s disease and melanoma: a systematic review and meta-analysis. Transl Neurodegener 4:21

    Article  PubMed  PubMed Central  Google Scholar 

  13. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6:e1000097

    Article  PubMed  PubMed Central  Google Scholar 

  14. Higgins JP, Green S (2011) Cochrane handbook for systematic reviews of interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration

  15. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA et al (1981) A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 30:239–245

    Article  CAS  PubMed  Google Scholar 

  16. Robinson E, Wajsbort J, Hirshowitz B (1973) Levodopa and malignant melanoma. Arch Pathol 95:213

    CAS  PubMed  Google Scholar 

  17. Lieberman AN, Shupack JL (1974) Levodopa and melanoma. Neurology 24:340

    Article  CAS  PubMed  Google Scholar 

  18. Sober AJ, Wick MM (1979) Levodopa and melanoma. JAMA 241:883–884

    Google Scholar 

  19. Bernstein JE, Medenica M, Soltani K, Solomon A, Lorincz AL (1980) Levodopa administration and multiple primary cutaneous melanomas. Arch Dermatol 116:1041–1044

    Article  CAS  PubMed  Google Scholar 

  20. Kochar AS (1985) Development of malignant melanoma after levodopa therapy for Parkinson’s disease. Am J Med 79:119–121

    Article  CAS  PubMed  Google Scholar 

  21. Rampen FHJ (1985) Levodopa and melanoma: three cases and review of literature. J Neurol Neurosurg Psychiatry 48:585–588

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Haider SA, Thaller VT (1992) Lid melanoma and parkinsonism. Br J Ophthalmol 76:246–247

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Pfützner W, Przybilla B (1997) Malignant melanoma and levodopa: is there a relationship? Two new cases and a review of the literature. J Am Acad Dermatol 37(2 Pt 2):332–336

    Article  PubMed  Google Scholar 

  24. Charles J, Templier I, Leroux D, Leroux D, Salameire D, Robert C, Lantuejoul S et al (2009) Twenty-two cutaneous primary melanomas in a patient with high genetic predisposition to melanoma receiving levodopa therapy for Parkinson’s disease. Pigment Cell Melanoma Res 22(6):851–853

    Article  CAS  PubMed  Google Scholar 

  25. Goetz CG (1983) Skin rash associated with Sinemet 25/100. N Engl J Med 309:1387–1388

    CAS  PubMed  Google Scholar 

  26. Chou KL, Stacy MA (2007) Skin rash associated with Sinemet does not equal levodopa allergy. Neurology 68(13):1078–1079

    Article  CAS  PubMed  Google Scholar 

  27. Cansino-Torres MA, Sandoval-Rodríguez V, Sáenz-Farret M (2018) Allergy to Carbidopa. Clin Neuropharmacol 41(2):75–79

    Article  PubMed  Google Scholar 

  28. Niedermaier G, Briner V (1997) Henoch-Schönlein syndrome induced by carbidopa/levodopa. Lancet 349(9058):1071–1072

    Article  CAS  PubMed  Google Scholar 

  29. Esteban-Fernandez L, Alonso-Canovas A, Rojas-Medina LM, Ballester-MartÍnez MA, Corral-Corral I, Martinez-Castrillo JC (2016) Carbidopa-induced eosinophilic fasciitis: A review. Neurol India 64(1):157–159

    Article  PubMed  Google Scholar 

  30. Joly P, Lampert A, Thomine E, Lauret P (1991) Development of pseudobullous morphea and scleroderma-like illness during therapy with l-5-hydroxytryptophan and carbidopa. J Am Acad Dermatol 25(2 Pt 1):332–333

    Article  CAS  PubMed  Google Scholar 

  31. Grainger KM (1971) Pigmentation in Parkinson’s disease treated with levodopa. Lancet 1:97–98

    Google Scholar 

  32. Reynolds NJ, Crossley J, Ferguson I, Peachey RD (1989) Darkening of white hair in Parkinson’s disease. Clin Exp Dermatol 14(4):317–318

    Article  CAS  PubMed  Google Scholar 

  33. Komagamine T, Suzuki K, Hirata K (2013) Darkening of white hair following levodopa therapy in a patient with Parkinson’s disease. Mov Disord 28(12):1643

    Article  PubMed  Google Scholar 

  34. Munhoz RP, Teive HA (2013) Darkening of white hair in Parkinson’s disease during use of levodopa rich Mucuna pruriens extract powder. Arq Neuropsiquiatr 71(2):133

    Article  PubMed  Google Scholar 

  35. Vega Gutiérrez J, Miranda Romero A, Martínez G, Torrero MV, Lopez de Juan M (2003) Hyperpigmentation mimicking Laugier syndrome, levodopa therapy and Addison’s disease. J Eur Acad Dermatol Venereol 17(3):324–327

    Article  PubMed  Google Scholar 

  36. Sabaté M, Bosch A, Pedrós C, Figueras A (1999) Vitiligo associated with tolcapone and levodopa in a patient with Parkinson’s disease. Ann Pharmacother 33(11):1228–1229

    PubMed  Google Scholar 

  37. Marshall A, Williams MJ (1971) Alopecia and levodopa. Br Med J 2(5752):47

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Parkinson Study Group (2000) A randomized controlled trial comparing pramipexole with levodopa in early Parkinson’s disease: design and methods of the CALM-PD study. Clin Neuropharmacol 23(1):34–44

    Article  Google Scholar 

  39. Stocchi F, Ruggieri S, Vacca L, Olanow CW (2002) Prospective randomized trial of lisuride infusion versus oral levodopa in patients with Parkinson’s disease. Brain 125(Pt 9):2058–2066

    Article  PubMed  Google Scholar 

  40. Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A et al (2004) Levodopa and the Progression of Parkinson’s Disease. N Engl J Med 351:2498–2508

    Article  CAS  PubMed  Google Scholar 

  41. Rascol O, Brooks DJ, Melamed E, Oertel W, Poewe W, Stocchi F et al (2005) Rasagiline as an adjunct to levodopa in patients with Parkinson’s disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet 365:947–954

    Article  CAS  PubMed  Google Scholar 

  42. Blindauer K, Shoulson I, Oakes D, Kieburtz K, Schwid S, Fahn S et al (2006) A randomized controlled trial of etilevodopa in patients with Parkinson disease who have motor fluctuations. Arch Neurol 63(2):210–216

    Article  PubMed  Google Scholar 

  43. Hauser RA, Hsu A, Kell S, Espay AJ, Sethi K, Stacy M et al (2013) Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson’s disease and motor fluctuations: a phase 3 randomized, double-blind trial. Lancet Neurol 12(4):346–356

    Article  CAS  PubMed  Google Scholar 

  44. Olanow CW, Kieburtz K, Odin P, Espay AJ, Standaert DG, Fernandez HH et al (2014) Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson’s disease: a randomised, controlled, double blind, double-dummy study. Lancet Neurol 13(2):141–149

    Article  CAS  PubMed  Google Scholar 

  45. Ferreira JJ, Lees A, Rocha J-F, Poewe W, Rascol O, Soares-da-Silva P, Bi-Park 1 investigators (2016) Opicapone as an adjunct to levodopa in patients with Parkinson’s disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial. Lancet Neurol 15(2):154–165

    Article  CAS  PubMed  Google Scholar 

  46. Siple JF, Schneider DC, Wanlass WA, Rosenblatt BK (2000) Levodopa therapy and the risk of malignant melanoma. Ann Pharmacother 34:382–385

    Article  CAS  PubMed  Google Scholar 

  47. Constantinescu R, Romer M, Kieburtz K (2007) Malignant melanoma in early Parkinson’s disease: the DATATOP trial. Mov Disord 22:720–722

    Article  PubMed  Google Scholar 

  48. Bose A, Petsko GA, Eliezer D (2018) Parkinson’s disease and melanoma: co-occurrence and mechanisms. J Parkinsons Dis 8(3):385–398

    Article  PubMed  PubMed Central  Google Scholar 

  49. Fiala KH, Whetteckey J, Manyam BV (2003) Malignant melanoma and levodopa in Parkinson’s disease: causality or coincidence? Parkinsonism Relat Disord 9:321–327

    Article  PubMed  Google Scholar 

  50. Paisán-Ruiz C, Houlden H (2010) Common pathogenic pathways in melanoma and Parkinson disease. Neurology 75(18):1653–1655

    Article  PubMed  Google Scholar 

  51. Olsen J, Tangerud K, Wermuth L, Frederiksen K, Friis S (2007) Treatment with levodopa and risk for malignant melanoma. Mov Disord 22(9):1252–1257

    Article  PubMed  Google Scholar 

  52. Miwa H, Kondo T (2003) Hair loss induced by dopamine agonist: case report and review of the literature. Parkinsonism Relat Disord 10(1):51–52

    Article  PubMed  Google Scholar 

  53. Peters EMJ, Maurer M, Botchkarev VA, Gordon DS, Paus R (1999) Hair growth-modulation by adrenergic drugs. Exp Dermatol 8:274–281

    Article  CAS  PubMed  Google Scholar 

  54. Foitzik K, Krause K, Nixon AJ, Ford CA, Ohnemus U, Pearson AJ et al (2003) Prolactin and its receptor are expressed in murine hair follicle epithelium, show hair cycle-dependent expression, and induce catagen. Am J Pathol 162:1611–1621

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Horvat J, Stojić Z, Janković BD (1991) Effect of dopamine, L-dopa, carbidopa and L-dopa/carbidopa on arthus and delayed hypersensitivity skin reactions in the rat. Int J Neurosci 59(1–3):199–203

    Article  CAS  PubMed  Google Scholar 

  56. Brown SG (2004) Clinical features and severity grading of anaphylaxis. J Allergy Clin Immunol 114(2):371–376

    Article  PubMed  Google Scholar 

  57. Cicero CE, Nicoletti A, Mostile G, Zappia M (2016) A case of severe leg oedema in a patient with Parkinson’s disease treated with pramipexole. Postgrad Med J 92(1090):484

    Article  PubMed  Google Scholar 

  58. Epstein M, Johnson DA, Hawes R, Schmulewitz N, Vanagunas AD, Gossen ER et al (2016) Long-term PEG-J tube safety in patients with advanced Parkinson’s disease. Clin Transl Gastroenterol 7:e159

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. 1st Department of Neurology and Movement Disorders, National and Kapodistrian University of Athens, Medical School, Aeginition Hospital, 72-74 Vasilissis Sofias Avenue, 11528, Athens, Greece

    Anastasia Bougea, Nikolaos Spantideas & Leonidas Stefanis

  2. 2nd Department of Dermatology and Venereology, National and Kapodistrian University of Athens, Medical School, “Attikon” General University Hospital, Athens, Greece

    Alexandros Katoulis

Authors
  1. Anastasia Bougea
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nikolaos Spantideas
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Alexandros Katoulis
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Leonidas Stefanis
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Anastasia Bougea.

Ethics declarations

Conflict of interest

There is no conflict of interest.

Ethical approval

This manuscript does not contain any studies with human participants or animals performed by any of the authors.

Informed consent

My work compose a review of studies without inclusion of patients details that could lead to patients identification. For this type of study/report formal consent is not required.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bougea, A., Spantideas, N., Katoulis, A. et al. Levodopa-induced skin disorders in patients with Parkinson disease: a systematic literature review approach. Acta Neurol Belg 119, 325–336 (2019). https://doi.org/10.1007/s13760-019-01195-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13760-019-01195-3

Keywords

Search

Navigation